Proteome Sciences, Buck Institute Partner on Test for Breast Cancer Treatment Response | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Proteome Sciences and the Buck Institute for Research on Aging announced today a collaboration to develop mass spectrometry-based tests aimed at improving response to breast cancer therapies.

Under the terms of the deal, Proteome Sciences will support the development of mass spec assays that measure changes in estrogen receptor alpha, a biomarker associated with response to anti-estrogen therapies for breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.